SCHEMBL6638516

SCHEMBL6638516

O=C(OS(=O)(=O)C(F)(F)F)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
F2 P00734 1/20 0.50
TSHR P16473 4/20 0.47
CES1 P23141 2/20 0.47
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
TDP1 Q9NUW8 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HSD17B10 Q99714 2/20 0.44
TP53 P04637 1/20 0.42
MAPT P10636 5/20 0.41
NPSR1 Q6W5P4 2/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
DAO P14920 1/20 0.39
NAPRT Q6XQN6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28573797 0.89 PDCD1 (0.49) MAPTSMN1; SMN2L3MBTL1
SCHEMBL21408400 0.89 ATM (0.41) LMNAF2CES1TDP1MAPT
SCHEMBL28830274 0.86 TSHR (0.46) TSHRALDH1A1HSD17B10TP53KMT2A
SCHEMBL404698 0.85 MAPK1 (0.38) LMNAF2TSHRCES1MAPK1
SCHEMBL28564573 0.85 CES2 (0.43) CES1MAPK1MAPTKMT2ASMN1; SMN2
SCHEMBL28841642 0.83 CES2 (0.52) TSHRCES1KMT2ACES2MEN1
SCHEMBL778826 0.83 TDP1 (0.50) LMNACES1TDP1ALDH1A1MAPT
SCHEMBL776559 0.81 KMT2A (0.47) MAPK1ALDH1A1MAPTKMT2APOLB
SCHEMBL28747778 0.81 POLB (0.51) LMNATSHRALDH1A1KMT2APOLB
SCHEMBL9418408 0.81 CES2 (0.49) LMNACES1MAPK1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150390-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-05-09 US claimed
EP-4286393-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE Daiichi Sankyo Company, Limited (JP) 2023-12-06 EP claimed
CN-116867795-A Novel method for producing antibody-immunostimulant conjugate 第一三共株式会社 2023-10-10 CN claimed
WO-2022163846-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE 第一三共株式会社 2022-08-04 WO claimed
US-20240150390-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-05-09 US disclosed
CN-113354811-B Oxazoline polymer with side chain containing amino and/or hydroxyl, preparation method and application thereof 华东理工大学 2024-05-07 CN disclosed
WO-2024024935-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT 第一三共株式会社 2024-02-01 WO disclosed
EP-4286393-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE Daiichi Sankyo Company, Limited (JP) 2023-12-06 EP disclosed
CN-116867795-A Novel method for producing antibody-immunostimulant conjugate 第一三共株式会社 2023-10-10 CN disclosed
WO-2022163846-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE 第一三共株式会社 2022-08-04 WO disclosed
CN-110317322-B Particulate amine-functionalized polyaryletherketone polymers and copolymers thereof 塞特工业公司 2022-06-14 CN disclosed
CN-113354811-A Oxazoline polymer with side chain containing amino and/or hydroxyl, preparation method and application thereof 华东理工大学 2021-09-07 CN disclosed
WO-2002090347-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-14 WO disclosed
US-20020026052-A1 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 2002-02-28 US disclosed
EP-0366301-B1 Preparation of 1,4-diazabicyclo [3.2.2]nonane PFIZER (US) 1994-08-31 EP disclosed
US-5026845-A 1,4-diazabicyclo[3.2.2.]nonane and intermediates for the preparation thereof FRIEDMANN ROBERT C (US) 1991-06-25 US disclosed
US-5026845-A 1,4-diazabicyclo[3.2.2.]nonane and intermediates for the preparation thereof FRIEDMANN ROBERT C (US) 1991-06-25 US disclosed
EP-0366301-A2 Preparation of 1,4-diazabicyclo [3.2.2]nonane PFIZER INC. (US) 1990-05-02 EP disclosed
US-4895943-A Preparation of 1,4-diazabicyclo(3.2.2)nonane PFIZER INC. (US) 1990-01-23 US disclosed
US-4895943-A Preparation of 1,4-diazabicyclo(3.2.2)nonane PFIZER INC. (US) 1990-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150390-A1 NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE PAICS, COASY, CDS2 LMNA 4487/4885F2 2900/4885TSHR 2895/4885
US-20020026052-A1 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors PKD1, PKD2, CSNK1A1 LMNA 520/4885F2 2334/4885TSHR 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.